Cardon Lon 4

What Happened

• Lon Cardon, a director of Mirum Pharmaceuticals, was granted equity awards on 2026-06-15: 3,772 derivative awards (grant, $0.00 acquisition price) and 1,980 restricted stock units (RSUs, $0.00). The grants have no cash purchase price at issuance; combined they total 5,752 award units.

Key Details

• Transaction date: 2026-06-15; Form 4 filed: 2026-06-17 (timely filing).
• Instrument types and amounts: 3,772 derivative awards (A) and 1,980 RSUs (A), both reported with $0.00 acquisition price.
• Vesting: Both awards vest on the first anniversary of the grant; in any case they will be fully vested by the issuer’s 2027 annual stockholder meeting (see footnotes F1 and F2).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Transaction code: "A" = Grant/Award. These are compensation grants, not open-market purchases or sales.

Context

• RSUs represent a contingent right to receive shares upon vesting; the 3,772 derivatives appear to be an option-style award (also subject to vesting). Awards create potential future ownership if vesting conditions are met, but do not involve immediate cash exchanged or an immediate sale of shares.
• Such director equity grants are common as compensation and should be interpreted as compensation-related awards rather than direct market purchases or sales.